Back to Search
Start Over
Activity and mechanism of action of antimicrobial peptide ACPs against Candida albicans.
- Source :
-
Life sciences [Life Sci] 2024 Aug 01; Vol. 350, pp. 122767. Date of Electronic Publication: 2024 Jun 04. - Publication Year :
- 2024
-
Abstract
- Aims: Candida albicans is the most prevalent pathogenic fungus, exhibiting escalating multidrug resistance (MDR). Antimicrobial peptides (AMPs) represent promising candidates for addressing this issue. In this research, five antimicrobial peptides, ACP1 to ACP5 which named ACPs were studied as alternative fungicidal molecules.<br />Main Methods: CD assay was used to analyze the 2D structures, Absorbance method was used to test the antimicrobial activity, haemolytic activity, time-kill kinetics, biofilm inhibition and reduction activity, resistance induction activity and assessment against fluconazole-resistant C. albicans. SEM, TEM, CLSM, flow cytometer and FM were carried out to provide insight into the mechanisms of anti-Candida action.<br />Key Findings: ACPs possessed an α-helical structure and strong anti-Candida activities, with minimum inhibitory concentrations (MICs) from 3.9 to 15.6 μg/mL. In addition, ACPs did not produce hemolysis at concentrations lower than 10 or 62 × MIC, indicating their low cytotoxicity. Fungicidal kinetics showed that they completely killed C. albicans within 8 h at 2 to 4 × MIC. Notably, ACPs were highly fungicidal against fluconazole-resistant C. albicans and showed low resistance. In addition, they were effective in inhibiting mycelium and biofilm formation. Fluorescence microscopy revealed that while fluconazole had minimal to no inhibitory effect on biofilm-forming cells, ACPs induced apoptosis in all of them. The research on mechanism of action revealed that ACPs disrupted the cell membranes, with ROS increasing and cellular mitochondrial membrane potential decreasing.<br />Significance: ACPs could be promising candidates for combating fluconazole-resistant C. albicans infections.<br />Competing Interests: Declaration of competing interest The authors declare that they have no conflicts of interest.<br /> (Copyright © 2024. Published by Elsevier Inc.)
- Subjects :
- Drug Resistance, Fungal drug effects
Hemolysis drug effects
Humans
Membrane Potential, Mitochondrial drug effects
Candida albicans drug effects
Microbial Sensitivity Tests
Antifungal Agents pharmacology
Antifungal Agents chemistry
Biofilms drug effects
Antimicrobial Peptides pharmacology
Antimicrobial Peptides chemistry
Fluconazole pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0631
- Volume :
- 350
- Database :
- MEDLINE
- Journal :
- Life sciences
- Publication Type :
- Academic Journal
- Accession number :
- 38843993
- Full Text :
- https://doi.org/10.1016/j.lfs.2024.122767